Evidence map›Paper›PMID 39198664›Full record

ArticleActa pharmacologica Sinica2025

Author Correction: Discovery of a selective TRF2 inhibitor FKB04 induced telomere shortening and senescence in liver cancer cells.

Yin-da Qiu, Qi Yan, Yi Wang, Yan-Fei Ye, Yan Wang, Meng-Ying Wang, Pei-Pei Wang, Shu-Yuan Zhang, Da-Long Wang, Hao Yan and 7 more

Abstract readPublished Erratum
In one paragraph

Article in Acta pharmacologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Yin-da Qiu *School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Qi Yan *School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Yi Wang *School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Yan-Fei YeSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Yan WangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Meng-Ying WangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Pei-Pei WangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Shu-Yuan ZhangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Da-Long WangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Hao YanSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Jing RuanDepartment of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, China. ruanjing850617@163.com.
Yun-Jie ZhaoSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Le-Hao HuangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Namki ChoCollege of Pharmacy, Chonnam National University, Gwangju, 61186, Republic of Korea.
Kun WangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China.
Xiao-Hui ZhengSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China. zhengxh@wmu.edu.cn.
Zhi-Guo LiuSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, China. lzgcnu@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39198664
PMCPMC11747458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.